Dried Blood Assessment Equivalent to Drawn Blood Samples
|
By LabMedica International staff writers Posted on 14 Aug 2017 |
|
A self-sampling method for therapeutic drug monitoring (TDM) of biologicals was developed that should enhance TDM implementation by patients with various autoimmune conditions.
Investigators at the Sanquin Blood Supply Foundation (Amsterdam, the Netherlands) used the rheumatoid arthritis treatment drug adalimumab to establish the feasibility of replacing drawn blood samples with dried blood spots obtained by finger prick.
Adalimumab is a TNF-inhibiting, anti-inflammatory medication. It binds to tumor necrosis factor-alpha (TNFalpha), which normally binds to TNFalpha receptors, leading to the inflammatory response of autoimmune diseases. By binding to TNFalpha, adalimumab reduces this inflammatory response. Because TNFalpha is also part of the immune system, which protects the body from infection, treatment with adalimumab may increase the risk of infections. For this reason the U.S. Food and Drug Administration issued a black box warning to doctors, which appears in the product labeling of adalimumab and other TNF-inhibiting drugs, instructing them to screen and monitor potential patients more carefully.
The investigators compared adalimumab and anti-adalimumab antibody (ADA) concentration measurements in dried blood spots (DBS) obtained from finger pricks with measurements in serum obtained via venipuncture, from 161 patients with rheumatic inflammatory diseases. Adalimumab and ADA concentration were assessed by ELISA and antigen binding test (ABT), respectively.
Results revealed that adalimumab and ADA concentrations obtained by the finger prick/DBS method correlated well with serum results from the same patient (correlation coefficient greater than 0.87). Interestingly, antibody concentrations (adalimumab, ADA, or total immunoglobulin G) in DBS from finger prick, but not albumin, were systematically lower compared to serum. Experiments on spiked blood samples demonstrated a quantitative recovery for all tested proteins in DBS, suggesting a slightly different protein composition of blood collected via finger prick versus venipuncture. Therefore, the investigators established a correction factor of approximately 1.2 to relate finger prick/DBS values to serum values.
"Easy home sampling at different time points will benefit patients and could help to prescribe biologics optimally," said senior author Dr. Karien Bloem, post-doctoral researcher in immunopathology at Sanquin Blood Supply Foundation.
The study was published in the August 9, 2017, online edition of the British Journal of Clinical Pharmacology.
Related Links:
Sanquin Blood Supply Foundation
Investigators at the Sanquin Blood Supply Foundation (Amsterdam, the Netherlands) used the rheumatoid arthritis treatment drug adalimumab to establish the feasibility of replacing drawn blood samples with dried blood spots obtained by finger prick.
Adalimumab is a TNF-inhibiting, anti-inflammatory medication. It binds to tumor necrosis factor-alpha (TNFalpha), which normally binds to TNFalpha receptors, leading to the inflammatory response of autoimmune diseases. By binding to TNFalpha, adalimumab reduces this inflammatory response. Because TNFalpha is also part of the immune system, which protects the body from infection, treatment with adalimumab may increase the risk of infections. For this reason the U.S. Food and Drug Administration issued a black box warning to doctors, which appears in the product labeling of adalimumab and other TNF-inhibiting drugs, instructing them to screen and monitor potential patients more carefully.
The investigators compared adalimumab and anti-adalimumab antibody (ADA) concentration measurements in dried blood spots (DBS) obtained from finger pricks with measurements in serum obtained via venipuncture, from 161 patients with rheumatic inflammatory diseases. Adalimumab and ADA concentration were assessed by ELISA and antigen binding test (ABT), respectively.
Results revealed that adalimumab and ADA concentrations obtained by the finger prick/DBS method correlated well with serum results from the same patient (correlation coefficient greater than 0.87). Interestingly, antibody concentrations (adalimumab, ADA, or total immunoglobulin G) in DBS from finger prick, but not albumin, were systematically lower compared to serum. Experiments on spiked blood samples demonstrated a quantitative recovery for all tested proteins in DBS, suggesting a slightly different protein composition of blood collected via finger prick versus venipuncture. Therefore, the investigators established a correction factor of approximately 1.2 to relate finger prick/DBS values to serum values.
"Easy home sampling at different time points will benefit patients and could help to prescribe biologics optimally," said senior author Dr. Karien Bloem, post-doctoral researcher in immunopathology at Sanquin Blood Supply Foundation.
The study was published in the August 9, 2017, online edition of the British Journal of Clinical Pharmacology.
Related Links:
Sanquin Blood Supply Foundation
Gold Member
Hybrid Pipette
SWITCH
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Alcohol Testing Device
Dräger Alcotest 7000
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read more
Hematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channel
Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Microbiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more
AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read more
Pathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read more
Technology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read more
Aptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more